X
[{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Anavo Therapeutics"},{"orgOrder":0,"company":"Frame Cancer Therapeutics","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"$33.3 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Frame Cancer Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"Sotio","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Sotio
Deal Size: $740.0 million
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
October 16, 2023
Details:
An additional application of Frame’s technology is the development of personalized cancer vaccines, thereby leveraging the full antigenic potential of a tumor. CureVac will refocus development of personalized cancer vaccines on an mRNA modality.
Lead Product(s):
mRNA Cancer Vaccine
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Vaccine
Partner/Sponsor/Collaborator:
CureVac
Deal Size: $33.3 million
Upfront Cash: Undisclosed
Deal Type: Acquisition
June 08, 2022
Details:
The funds will be used to advance a proprietary drug discovery portfolio in oncology and establish a versatile and robust platform to address the target space broadly across multiple indications.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Small molecule
Partner/Sponsor/Collaborator:
M Ventures
Deal Size: $24.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
April 22, 2021